Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$268.92MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey Dayno
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 293
- Beta
- 0.98
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.99
Financials
Revenue
$268.92M+4385.7%Net Income
$48.20MEBITDA
$68.28MFree Cash Flow
$76.69MEPS (diluted)
$0.81Shares Outstanding (diluted)
59.68M+8.0%Operating Expenses
$134.03MCash & Debt
$771.14MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $868.45M | $158.69M | $2.76 |
| 2024 | $714.73M | $145.49M | $2.56 |
| 2023 | $582.02M | $128.85M | $2.17 |
| 2022 | $437.86M | $181.47M | $3.07 |
| 2021 | $305.44M | $34.60M | $0.60 |
| 2020 | $159.74M | $-36.94M | $-1.12 |
| 2019 | $6.00M | $-151.98M | $-2.94 |
| 2018 | $0.00 | $-39.90M | $-1.42 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.06
- Implied price
- $56.78
- Return from $33.76
- 11.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $28.23 — -16.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -2.0% | -5.9% | -2.4% | 0.7% | 3.4% | 5.9% |
| 3.0% | -1.1% | 2.6% | 5.8% | 8.7% | 11.3% |
| 8.0% | 3.7% | 7.6% | 11.0% | 14.0% | 16.7% |
| 13.0% | 8.5% | 12.6% | 16.1% | 19.2% | 22.1% |
| 18.0% | 13.3% | 17.6% | 21.2% | 24.5% | 27.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (16)
- Newsglobenewswire.com·3d ago·Neutral
Harmony Biosciences to Participate in Upcoming Investor Conferences PLYMOUTH MEETING, Pa., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in the following upcoming investor conferences.
View source ↗ - Newszacks.com·17d ago·Negative
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
Harmony Biosciences Q3 Earnings Call Highlights Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.
View source ↗ - Newszacks.com·31d ago·Neutral
HRMY or ARGX: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newszacks.com·31d ago·Positive
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗ - Newsbarrons.com·31d ago·Positive
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences Technical indicators have turned bullish for the Barron's Investor Circle stock picks.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It Harmony Biosciences is rated Buy with a 12-month price target of $43, reflecting strong cash generation and WAKIX growth. HRMY's valuation is supported by WAKIX's robust performance, cash reserves, and limited downside if patents hold through 2030. Key risks include the pending AET patent litigation and management turnover, with significant near-term binary events ahead.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on November 4, 2026, at 8:30 a.m. ET to discuss the results.
View source ↗ - Newszacks.com·37d ago·Positive
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.
View source ↗ - Newsfool.com·41d ago·Negative
Why Harmony Biosciences Stock Got Mashed on Monday Investors weren't cheered by a major change in the company's leadership.
View source ↗ - Newszacks.com·47d ago·Negative
HRMY vs. CSLLY: Which Stock Is the Better Value Option? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
View source ↗ - Newszacks.com·47d ago·Positive
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗ - Newsglobenewswire.com·52d ago·Positive
…nounces Poster Presentation at the 17th European Narcolepsy Days PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.
View source ↗ - Newsglobenewswire.com·80d ago·Positive
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece.
View source ↗ - Newsmarketbeat.com·100d ago·Neutral
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $1.09 per share
Typical surprise -12.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.81 vs $1.09miss
- Tue, Aug 4$1.28 vs $0.96beat
- Thu, May 7$0.55 vs $0.76miss
- Tue, Feb 24$0.38 vs $0.84miss
- Tue, Nov 4$0.87 vs $0.92miss
- Tue, Aug 5$0.68 vs $0.78miss
Estimates and results for HRMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HRMY officers and directors.
- Bought
- —
- Sold
- $5.9m
0 trades
13 trades
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Kapadia Sandipsold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HRMY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
